REFERENCES
1. Bazo-Alvarez JC, Nimmons D, Walters K, Petersen I, Schrag A. Risk of Parkinson’s disease in people aged ≥ 50 years with new-onset anxiety: a retrospective cohort study in UK primary care. Br J Gen Pract. 2024;74:e482-8.
2. Minato T, Maeda T, Fujisawa Y, et al. Progression of Parkinson’s disease is associated with gut dysbiosis: two-year follow-up study. PLoS One. 2017;12:e0187307.
3. Hussein A, Guevara CA, Del Valle P, Gupta S, Benson DL, Huntley GW. Non-motor symptoms of Parkinson’s disease: the neurobiology of early psychiatric and cognitive dysfunction. Neuroscientist. 2021;29:97-116.
4. Moustafa AA, Chakravarthy S, Phillips JR, et al. Motor symptoms in Parkinson’s disease: A unified framework. Neurosci Biobehav Rev. 2016;68:727-40.
5. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46:989-93.
6. Borgonovo J, Allende-Castro C, Laliena A, Guerrero N, Silva H, Concha ML. Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson’s disease. Parkinsonism Relat Disord. 2017;35:17-24.
7. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23:183-9.
8. Usnich T, Hauptmann B, Hanssen H, et al. Depressive symptoms in Parkinson’s disease are insufficiently but more often treated than in other chronic conditions. NPJ Parkinsons Dis. 2023;9:113.
9. Jellinger KA. The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm. 2022;129:1397-418.
10. Khedr EM, Abdelrahman AA, Elserogy Y, Zaki AF, Gamea A. Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life. Egypt J Neurol Psychiatry Neurosurg. 2020;56:116.
11. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG. Cognitive impairments and depression in Parkinson’s disease: a follow up study. J Neurol Neurosurg Psychiatry. 1990;53:597-602.
12. Burchill E, Watson CJ, Fanshawe JB, et al. The impact of psychiatric comorbidity on Parkinson’s disease outcomes: a systematic review and meta-analysis. Lancet Reg Health Eur. 2024;39:100870.
13. Jones JD, Kurniadi NE, Kuhn TP, Szymkowicz SM, Bunch J, Rahmani E. Depressive symptoms precede cognitive impairment in de novo Parkinson’s disease patients: Analysis of the PPMI cohort. Neuropsychology. 2019;33:1111-20.
14. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease - epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8:35-47.
15. Prange S, Klinger H, Laurencin C, Danaila T, Thobois S. Depression in patients with Parkinson’s Disease: current understanding of its neurobiology and implications for treatment. Drugs Aging. 2022;39:417-39.
16. Wang Z, Wei H, Xin Y, Qin W. Advances in the study of depression and anxiety in Parkinson’s disease: a review. Medicine. 2025;104:e41674.
17. Surguchov A, Surguchev A. Synucleins: New data on misfolding, aggregation and role in diseases. Biomedicines. 2022;10:3241.
18. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469-80.e12.
19. Boertien JM, Murtomäki K, Pereira PA, et al. Gut microbiome alterations in fecal samples of treatment-naïve de novo Parkinson’s disease patients. Neurology 2022.
20. Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99:1877-2013.
21. Ostrakhovitch EA, Ono K, Yamasaki TR. Metabolomics in Parkinson’s disease and correlation with disease state. Metabolites. 2025;15:208.
22. Suleiman Khoury Z, Sohail F, Wang J, et al. Neuroinflammation: a critical factor in neurodegenerative disorders. Cureus. 2024.
23. Hesse S, Meyer PM, Strecker K, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2008;36:428-35.
24. Chagas MHN, Linares IM, Garcia GJ, Hallak JE, Tumas V, Crippa JAS. Neuroimaging of depression in Parkinson’s disease: a review. Int Psychogeriatr. 2013;25:1953-61.
25. Lin Y, Paul KC, Jones DP, et al. Metabolomic profiles of depression in Parkinson’s disease patients. NPJ Parkinsons Dis. 2025;12:9.
26. Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology. 1984;34:642.
27. Rodríguez-Antigüedad J, Olmedo-Saura G, Pagonabarraga J, Martínez-Horta S, Kulisevsky J. Approaches for treating neuropsychiatric symptoms in Parkinson’s disease: a narrative review. Ther Adv Neurol Disord. 2025;18:17562864251336903.
28. Marsh L. Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep. 2013;13:409.
29. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2007;22:1077-92.
30. Fakhoury M. Revisiting the serotonin hypothesis: implications for major depressive disorders. Mol Neurobiol. 2016;53:2778-86.
31. Nie K, Li Y, Zhang J, et al. Distinct bile acid signature in Parkinson’s disease with mild cognitive impairment. Front Neurol. 2022;13:897867.
33. Wang S, Xu C, Liu H, et al. Connecting the gut microbiota and neurodegenerative diseases: the role of bile acids. Mol Neurobiol. 2023;60:4618-40.
34. Yoo JY, Groer M, Dutra SVO, Sarkar A, Mcskimming DI. Gut microbiota and immune system interactions. Microorganisms. 2020;8:1587.
35. Li Q, Meng LB, Chen LJ, et al. The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson’s disease. Front Neurol. 2023;14:1185375.
36. Tao J, An Y, Xu L, et al. The protective role of microbiota in the prevention of MPTP/P-induced Parkinson’s disease by resveratrol. Food Funct. 2023;14:4647-61.
37. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2023;19:275-93.
38. Chung SJ, Rim JH, Ji D, et al. Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson’s disease. Nutrition. 2021;83:111090.
39. Shin C, Lim Y, Lim H, Ahn TB. Plasma Short-Chain Fatty Acids in Patients With Parkinson’s Disease. Mov Disord. 2020;35:1021-7.
40. Pasricha TS, Guerrero-Lopez IL, Kuo B. Management of gastrointestinal symptoms in Parkinson’s disease: a comprehensive review of clinical presentation, workup, and treatment. J Clin Gastroenterol. 2024;58:211-20.
41. Jones JD, Dominguez B, Bunch J, Uribe C, Valenzuela Y, Jacobs JP. A bidirectional relationship between anxiety, depression and gastrointestinal symptoms in Parkinson’s disease. Clin Park Relat Disord. 2021;5:100104.
42. Shen T, Yue Y, He T, et al. The association between the gut microbiota and parkinson’s disease, a meta-analysis. Front Aging Neurosci. 2021;13:636545.
43. Gerhardt S, Mohajeri MH. Changes of colonic bacterial composition in Parkinson’s disease and other neurodegenerative diseases. Nutrients. 2018;10:708.
44. Heravi FS, Naseri K, Hu H. Gut microbiota composition in patients with neurodegenerative disorders (Parkinson’s and Alzheimer’s) and healthy controls: a systematic review. Nutrients. 2023;15:4365.
45. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30:350-8.
46. Barichella M, Severgnini M, Cilia R, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2018;34:396-405.
47. Yuan XY, Chen YS, Liu Z. Relationship among Parkinson’s disease, constipation, microbes, and microbiological therapy. World J Gastroenterol. 2024;30:225-37.
48. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57-62.
49. Jacob AA, Rout S, Dash R, et al. Gut microbiome differences in Parkinson’s disease patients in Central Kerala population. Neurodegener Dis Manag. 2026;16:299-309.
50. Hirayama M, Nishiwaki H, Hamaguchi T, Ohno K. Gastrointestinal disorders in Parkinson’s disease and other Lewy body diseases. NPJ Parkinsons Dis. 2023;9:71.
51. Chen M, Zhang Y, Hou L, et al. SVHRSP protects against rotenone-induced neurodegeneration in mice by inhibiting TLR4/NF-κB-mediated neuroinflammation via gut microbiota. NPJ Parkinsons Dis. 2025;11:43.
52. Abreu AE, Empadinhas N, Cardoso SM. Unveiling butyrate as a Parkinson’s disease therapy. Neurosci Bull. 2025;42:233-46.
53. Xie A, Ensink E, Li P, et al. Bacterial butyrate in Parkinson’s disease is linked to epigenetic changes and depressive symptoms. Mov Disord. 2022;37:1644-53.
54. De Mendonça IP, Da Silva RS, De Paiva IHR, et al. Prebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson’s disease by modulating butyrate-producing gut bacteria. Inflammopharmacology. 2026;34:2735-58.
55. Xie F, Tang G, Yang N, Chen J, Zou T. The study on the characteristics of gut microbiota in Parkinson disease with depression and its correlation with self-regulation psychological factors. Chin J Nerv Ment Dis. 2025;51:274-9.
57. Mittal R, Debs LH, Patel AP, et al. Neurotransmitters: the critical modulators regulating gut-brain axis. J Cell Physiol. 2017;232:2359-72.
58. Gurow K, Joshi DC, Gwasikoti J, Joshi N. Gut microbial control of neurotransmitters and their relation to neurological disorders: a comprehensive review. Horm Metab Res. 2025;57:315-25.
59. Dezfouli MA, Rashidi SK, Yazdanfar N, et al. The emerging roles of neuroactive components produced by gut microbiota. Mol Biol Rep. 2024;52:1.
60. Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease - Associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013;33:183-9.
61. Lian T, Guo P, Zuo LJ, et al. An investigation on the clinical features and neurochemical changes in Parkinson’s disease with depression. Front Psychiatry. 2019;9:723.
62. Lian T, Guo P, Zhang YN, et al. Parkinson’s Disease with depression: the correlations between neuroinflammatory factors and neurotransmitters in cerebrospinal fluid. Front Aging Neurosci. 2020;12:574776.
63. Villageliú D, Lyte M. Dopamine production in Enterococcus faecium: A microbial endocrinology-based mechanism for the selection of probiotics based on neurochemical-producing potential. PLoS One. 2018;13:e0207038.
64. Guerrero-Torres LE, García-Galindo JJ, Gómez-Galindo MF, et al. The gut microbiota in Parkinson’s disease: mechanistic insights into microbial-host interactions. Microorganisms. 2026;14:673.
65. Li C, Liang Y, Qiao Y. Messengers from the gut: gut microbiota-derived metabolites on host regulation. Front Microbiol. 2022;13:863407.
66. Van Treuren W, Dodd D. Microbial Contribution to the Human Metabolome: Implications for Health and Disease. Annu Rev Pathol. 2020;15:345-69.
67. Mccarville JL, Chen GY, Cuevas VD, Troha K, Ayres JS. Microbiota metabolites in health and disease. Annu Rev Immunol. 2020;38:147-70.
68. Wallen ZD, Appah M, Dean MN, et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 2020;6:11.
69. Chen SJ, Chen CC, Liao HY, et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology. 2022;98:e848-58.
70. Yang X, Ai P, He X, et al. Parkinson’s disease is associated with impaired gut-blood barrier for short-chain fatty acids. Mov Disord. 2022;37:1634-43.
71. Krueger ME, Boles JS, Simon ZD, et al. A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria. Neuroscience 2024.
72. Boktor JC, Sharon G, Verhagen Metman LA, et al. Integrated Multi-cohort analysis of the Parkinson’s disease gut metagenome. Mov Disord. 2023;38:399-409.
73. Hensen T, Thiele I. Metabolic modeling links gut microbiota to metabolic markers of Parkinson’s disease. Gut Microbes. 2025;17:2554195.
74. Moiseyenko A, Antonello G, Schonhoff AM, et al. Faecalibacterium prausnitzii, depleted in the Parkinson’s disease microbiome, improves motor deficits in α-synuclein overexpressing mice. NPJ Parkinsons Dis. 2026;12:94.
75. Wu G, Jiang Z, Pu Y, et al. Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients. BMC Neurol. 2022;22:13.
76. Huang B, Chau SWH, Liu Y, et al. Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Nat Commun. 2023;14:2501.
77. Canyelles M, Tondo M, Cedó L, Farràs M, Escolà-gil JC, Blanco-vaca F. Trimethylamine N-Oxide: A Link among Diet, Gut Microbiota, Gene regulation of liver and intestine cholesterol homeostasis and HDL function. Int J Mol Sci. 2018;19:3228.
78. Caradonna E, Abate F, Schiano E, et al. Trimethylamine-N-Oxide (TMAO) as a rising-star metabolite: implications for human health. Metabolites. 2025;15:220.
79. Mudimela S, Vishwanath NK, Pillai A, et al. Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders. Drug Discov Today. 2022;27:103334.
80. Boini KM, Hussain T, Li P, Koka SS. Trimethylamine-N-Oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. Cell Physiol Biochem. 2017;44:152-62.
81. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12:662-7.
82. Janeiro MH, Solas M, Orbe J, et al. Trimethylamine N-Oxide as a mediator linking peripheral to central inflammation: an in vitro study. Int J Mol Sci. 2023;24:17557.
83. Quan W, Qiao CM, Niu GY, et al. Trimethylamine N-Oxide exacerbates neuroinflammation and motor dysfunction in an acute MPTP mice model of Parkinson’s disease. Brain Sciences. 2023;13:790.
84. Ferreon ACM, Moosa MM, Gambin Y, Deniz AA. Counteracting chemical chaperone effects on the single-molecule α-synuclein structural landscape. Proc Natl Acad Sci U S A. 2012;109:17826-31.
85. Tu R, Xia J. Stroke and vascular cognitive impairment: the role of intestinal microbiota metabolite TMAO. CNS Neurol Disord Drug Targets. 2024;23:102-21.
86. Virameteekul S. Influence of gut microbiota-derived TMAO on disease severity in Parkinson’s disease. Mov Disord. 2025. Available from: https://www.mdsabstracts.org/abstract/influence-of-gut-microbiota-derived-tmao-on-disease-severity-in-parkinsons-disease/ [Last accessed on 23 Jul 2026].
87. Caspani G, Kennedy S, Foster JA, Swann J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb Cell. 2019;6:454-81.
88. Alam R, Abdolmaleky HM, Zhou JR. Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet B Neuropsychiatr Genet. 2017;174:651-60.
89. Wang W, Jiang S, Xu C, et al. Interactions between gut microbiota and Parkinson’s disease: the role of microbiota-derived amino acid metabolism. Front Aging Neurosci. 2022;14:976316.
90. Yan Z, Yang F, Cao J, et al. Alterations of gut microbiota and metabolome with Parkinson’s disease. Microb Pathog. 2021;160:105187.
91. Wu J, Li CS, Huang WY, et al. Gut microbiota promote the propagation of pathologic α-syn from gut to brain in a gut-originated mouse model of Parkinson’s disease. Brain Behav Immun. 2025;128:152-69.
92. Fan X, Xiao Z, Chen Y, et al. Interactions between gut microbiota and parkinson’s disease: the role of tryptophan metabolism. Cell Commun Signal. 2025;23:424.
93. Anderson G, Seo M, Berk M, Carvalho AF, Maes M. Gut permeability and microbiota in Parkinson’s disease: role of depression, tryptophan catabolites, oxidative and nitrosative stress and melatonergic pathways. Curr Pharm Des. 2016;22:6142-51.
94. Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23:716-24.
95. Wilson EN, Umans J, Swarovski MS, et al. Parkinson’s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction. NPJ Parkinsons Dis. 2025;11:96.
96. Rosas-Sánchez GU, Germán-Ponciano LJ, Puga-Olguín A, et al. Gut-brain axis in mood disorders: a narrative review of neurobiological insights and probiotic interventions. Biomedicines. 2025;13:1831.
97. Li P, Killinger BA, Ensink E, et al. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson’s disease. Metabolites. 2021;11:29.
98. Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology. 2018;136:251-9.
99. Quinn M, Mcmillin M, Galindo C, Frampton G, Pae HY, Demorrow S. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis. 2014;46:527-34.
100. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001;98:3369-74.
101. Ackerman HD, Gerhard GS. Bile acids in neurodegenerative disorders. Front Aging Neurosci. 2016;8:263.
102. Cuevas E, Burks S, Raymick J, et al. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease. Nutr Neurosci. 2022;25:1374-91.
103. Huang F, Pariante CM, Borsini A. From dried bear bile to molecular investigation: a systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders. Brain Behav Immun. 2022;99:132-46.
104. Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry. 2016;21:786-96.
105. Rudzki L, Stone TW, Maes M, Misiak B, Samochowiec J, Szulc A. Gut microbiota-derived vitamins - underrated powers of a multipotent ally in psychiatric health and disease. Prog Neuropsychopharmacol Biol Psychiatry. 2021;107:110240.
106. Fanet H, Capuron L, Castanon N, Calon F, Vancassel S. Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry. Curr Neuropharmacol. 2021;19:591-609.
107. Peterson AL, Murchison C, Zabetian C, et al. Memory, mood, and vitamin D in persons with Parkinson’s disease. J Parkinsons Disease. 2013;3:547-55.
108. Berg D, Supprian T, Hofmann E, et al. Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol. 1999;246:1186-93.
109. Feldmann A, Illes Z, Kosztolanyi P, et al. Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord. 2008;23:42-6.
110. Maillet A, Krack P, Lhommée E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016;139:2486-502.
111. Yu CD, Xu QJ, Chang RB. Vagal sensory neurons and gut-brain signaling. Curr Opin Neurobiol. 2020;62:133-40.
112. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264-76.
113. Jiang M, Kang L, Wang YL, et al. Mechanisms of microbiota-gut-brain axis communication in anxiety disorders. Front Neurosci. 2024;18:1501134.
114. Mcvey Neufeld KA, Kay S, Bienenstock J. Mouse strain affects behavioral and neuroendocrine stress responses following administration of probiotic Lactobacillus rhamnosus JB-1 or traditional antidepressant fluoxetine. Front Neurosci. 2018;12:294.
115. Siopi E, Galerne M, Rivagorda M, et al. Gut microbiota changes require vagus nerve integrity to promote depressive-like behaviors in mice. Mol Psychiatry. 2023;28:3002-12.
116. Belelli D, Lambert JJ, Wan MLY, Monteiro AR, Nutt DJ, Swinny JD. From bugs to brain: unravelling the GABA signalling networks in the brain-gut-microbiome axis. Brain. 2025;148:1479-506.
117. Dogra N, Mani RJ, Katare DP. The gut-brain axis: two ways signaling in Parkinson’s disease. Cell Mol Neurobiol. 2022;42:315-32.
118. Barandouzi ZA, Starkweather AR, Henderson WA, Gyamfi A, Cong XS. Altered composition of gut microbiota in depression: a systematic review. Front Psychiatry. 2020;11:541.
119. Altaib H, Badr Y, Suzuki T. Bifidobacteria and psychobiotic therapy: current evidence and future prospects. RAS. 2021;9:74-91.
120. Klann EM, Dissanayake U, Gurrala A, et al. The gut-brain axis and its relation to Parkinson’s disease: a review. Front Aging Neurosci. 2022;13:782082.
121. Liu T, Shen Y, Bai Y, et al. Longitudinal neuroimaging reveals divergent clinical associations of glymphatic dysfunction and dopaminergic degeneration in Parkinson’s disease. Hum Brain Mapp. 2026;47:e70477.
122. Ishant, Parvez SA, Kumar R. Emerging insights into gut microbiota and alpha-synuclein pathology in Parkinson’s disease. 2026.
123. Mulak A. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol. 2015;21:10609.
124. O’gorman Tuura RL, Baumann CR, Baumann-Vogel H. Beyond dopamine: GABA, glutamate, and the axial symptoms of parkinson disease. Front Neurol. 2018;9:806.
125. Terkelsen MH, Hvingelby VS, Pavese N. Molecular imaging of the GABAergic System in Parkinson’s disease and atypical parkinsonisms. Curr Neurol Neurosci Rep. 2022;22:867-79.
126. Sharma S, Taliyan R, Singh S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav Brain Res. 2015;291:306-14.
127. Wang Y, Liu H, Du XD, et al. Association of low serum BDNF with depression in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;41:73-8.
128. Makris AP, Karianaki M, Tsamis KI, Paschou SA. The role of the gut-brain axis in depression: endocrine, neural, and immune pathways. Hormones. 2021;20:1-12.
129. Zhu Z, Cheng Y, Liu X, et al. The microbiota-gut-brain axis in depression: unraveling the relationships and therapeutic opportunities. Front Immunol. 2025;16:1644160.
130. Farzi A, Fröhlich EE, Holzer P. Gut microbiota and the neuroendocrine system. Neurotherapeutics. 2018;15:5-22.
131. Bertollo AG, Santos CF, Bagatini MD, Ignácio ZM. Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Front Neurosci. 2025;19:1541075.
132. Huo R, Zeng B, Zeng L, et al. Microbiota modulate anxiety-like behavior and endocrine abnormalities in hypothalamic-pituitary-adrenal axis. Front Cell Infect Microbiol. 2017;7:489.
133. Troubat R, Barone P, Leman S, et al. Neuroinflammation and depression: a review. Eur J Neurosci. 2020;53:151-71.
134. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014;29:1010-8.
135. Du X, Pang TY. Is dysregulation of the HPA-axis a core pathophysiology mediating co-morbid depression in neurodegenerative diseases? Front Psychiatry. 2015;6:32.
136. Nazir MM, Ghaffar W, Mustafa G, Saeed S, Ijaz MU, Ashraf A. Modulating depression through the gut-brain axis: the role of gut microbiota in therapeutic interventions. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:16893-911.
137. Tran AA, De Smet M, Grant GD, Khoo TK, Pountney DL. Investigating the convergent mechanisms between major depressive disorder and Parkinson’s disease. Complex Psychiatry. 2021;6:47-61.
138. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25.
139. Wu S, Chen N, Wang C, So KF. Research focus and trends of the association between gut microbiota and neuroinflammation. Front Microbiol. 2025;16:1564717.
140. Gajewska A, Strzelecki D, Gawlik-Kotelnicka O. Ghrelin as a biomarker of “immunometabolic depression” and its connection with dysbiosis. Nutrients. 2023;15:3960.
141. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7:27.
142. Li Z, Liang H, Hu Y, et al. Gut bacterial profiles in Parkinson’s disease: a systematic review. CNS Neurosci Ther. 2023;29:140-57.
143. Zhang P, Jin W, Lyu Z, Lyu X, Li L. Study on the mechanism of gut microbiota in the pathogenetic interaction between depression and Parkinson ’s disease. Brain Res Bull. 2024;215:111001.
144. Lin C, Chen CC, Chiang HL, et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. J Neuroinflammation. 2019;16:129.
145. Stampanoni Bassi M, Gilio L, Galifi G, et al. Mood disturbances in newly diagnosed Parkinson’s Disease patients reflect intrathecal inflammation. Parkinsonism Relat Disord. 2024;122:106071.
146. Ramanzini LG, Camargo LFM, Silveira JOF, Bochi GV. Inflammatory markers and depression in Parkinson’s disease: a systematic review. Neurol Sci. 2022;43:6707-17.
147. Santiago RM. Depression in Parkinson’s disease is associated with a serotoninergic system change secondary to neuroinflammation. Int J Neurol Neurother. 2016;3:061.
148. Azam S, Jakaria M, Kim I, Kim J, Haque ME, Choi D. Regulation of toll-like receptor (TLR) signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: focus on TLR4 signaling. Front Immunol. 2019;10:1000.
149. Hughes CD, Choi ML, Ryten M, et al. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis. Acta Neuropathol. 2019;137:103-20.
150. Ortega MA, Alvarez-Mon MA, García-Montero C, et al. Gut microbiota metabolites in major depressive disorder-deep insights into their pathophysiological role and potential translational applications. 2022;12:50.
151. Paul KC, Kusters C, Furlong M, et al. Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson’s disease patients. Brain Behav Immun Health. 2022;26:100530.
152. Pessoa Rocha N, Reis HJ, Vanden Berghe P, Cirillo C. Depression and cognitive impairment in Parkinson’s disease: a role for inflammation and immunomodulation? Neuroimmunomodulation. 2014;21:88-94.
153. Panaitescu P, Răzniceanu V, Mocrei-Rebrean ȘM, et al. The effect of gut microbiota-targeted interventions on neuroinflammation and motor function in Parkinson’s disease animal models - a systematic review. Curr Issues Mol Biol. 2024;46:3946-74.
154. Abdel-Haq R, Schlachetzki JCM, Glass CK, Mazmanian SK. Microbiome-microglia connections via the gut-brain axis. J Exp Med. 2019;216:41-59.
155. Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnet PW. Psychobiotics and the manipulation of bacteria-gut-brain signals. Trends Neurosci. 2016;39:763-81.
156. Breit S, Kupferberg A, Rogler G, Hasler G. Vagus Nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. Front Psychiatry. 2018;9:44.
157. Skowron K, Budzyńska A, Wiktorczyk-Kapischke N, et al. The role of psychobiotics in supporting the treatment of disturbances in the functioning of the nervous system - a systematic review. Int J Mol Sci. 2022;23:7820.
158. DÜdÜkÇÜ N, ÖĞÜt S. Psychobiotics and elderly health. Psikiyatride Güncel Yaklaşımlar. 2022;14:469-76.
159. Park JM, Lee SC, Ham C, Kim YW. Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: a meta-analysis of randomized controlled trials. Gut Pathog. 2023;15:9.
160. Li J, Wang J, Wang M, et al. Bifidobacterium: a probiotic for the prevention and treatment of depression. Front Microbiol. 2023;14:1174800.
161. Kaur H, Ali SA. Probiotics and gut microbiota: mechanistic insights into gut immune homeostasis through TLR pathway regulation. Food Funct. 2022;13:7423-47.
162. Gu F, Wu Y, Liu Y, Dou M, Jiang Y, Liang H. Lactobacillus casei improves depression-like behavior in chronic unpredictable mild stress-induced rats by the BDNF-TrkB signal pathway and the intestinal microbiota. Food Funct. 2020;11:6148-57.
163. Tette FM, Kwofie SK, Wilson MD. Therapeutic anti-depressant potential of microbial GABA produced by Lactobacillus rhamnosus strains for GABAergic signaling restoration and inhibition of addiction-induced HPA axis hyperactivity. Curr Issues Mol Biol. 2022;44:1434-51.
164. Zhu G, Zhao J, Zhang H, Chen W, Wang G. Administration of Bifidobacterium breve improves the brain function of Aβ1-42-Treated mice via the modulation of the gut microbiome. Nutrients. 2021;13:1602.
165. Tian P, Chen Y, Zhu H, et al. Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial. Brain Behav Immun. 2022;100:233-41.
166. Zhang T, Li Q, Cheng L, Buch H, Zhang F. Akkermansia muciniphila is a promising probiotic. Microb Biotechnol. 2019;12:1109-25.
167. Colliou N, Ge Y, Sahay B, et al. Commensal Propionibacterium strain UF1 mitigates intestinal inflammation via Th17 cell regulation. J Clin Invest. 2017;127:3970-86.
168. Ojukwu EA, Ojukwu VE, Davis J-M. Evaluating probiotic therapy as a gut-brain microbiota and neuroinflammation modulator in Parkinson’s disease: a systematic review. Junior Res. 2025;3:27-41.
169. Sun H, Zhao F, Liu Y, et al. Probiotics synergized with conventional regimen in managing Parkinson’s disease. NPJ Parkinsons Dis. 2022;8:62.
170. Hsieh TH, Kuo CW, Hsieh KH, et al. Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson’s disease. Brain Sci. 2020;10:206.
171. Yuan X, Chai J, Xu W, Zhao Y. Exploring the potential of probiotics and prebiotics in major depression: from molecular function to clinical therapy. Probiotics Antimicro Proteins. 2024;16:2181-217.
172. Choneva M, Shishmanova-Doseva M, Dimov I, et al. Xylooligosaccharides and aerobic training regulate metabolism and behavior in rats with streptozotocin-induced type 1 diabetes. Open Med. 2022;17:1632-44.
173. Huang H, Xu H, Luo Q, et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation: a case report. Medicine. 2019;98:e16163.
174. Song C, Lang W, Meng L, Ping W, Ge J. Plant-derived natural products improve disease: focus on gut-brain axis. Food Sci Hum Wellness. 2026;15:9250430.
175. Shin Y, Lee D, Kim JY, et al. Effect of fermented red ginseng on gut microbiota dysbiosis- or immobilization stress-induced anxiety, depression, and colitis in mice. J Ginseng Res. 2023;47:255-64.
176. Li P, Song C. Functional foods and Parkinson’s disease: a focus on omega-3 fatty acids. In: Aliani M, Eskin MNA, Editors. Functional Foods and Chronic Disease. 2024. pp. 175-86.
178. Pokora B, Pokora K, Binienda A, Fichna J. The ketogenic diet in Parkinson’s disease: a potential therapeutic strategy. Pharmacol Rep. 2025;77:1491-513.
179. García Milla P, Nieto Martínez G, Maulen M, Tapia C, Díaz W. The effect of supplementation with prebiotic fiber on the gut microbiota of a group of older people with Parkinson’s disease from the city of Santiago de Chile. a pilot study. Nutr Hosp. 2025;42:232-42.
180. Davis L, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010;144:285-92.
181. Scheperjans F, Levo R, Bosch B, et al. Fecal microbiota transplantation for treatment of parkinson disease: a randomized clinical trial. JAMA Neurol. 2024;81:925-38.
182. Sanzone J, Life M, Reiss D, et al. Uses of fecal microbiota transplantation in neurodegenerative disease: a scoping review. Cureus. 2024;16:e62265.
183. Li M, Wang K, Liu J, et al. Associations between dietary habits and depressive disorder: a diet-wide Mendelian randomization study. Medicine. 2026;105:e47516.
184. Martin SE, Kraft CS, Ziegler TR, Millson EC, Rishishwar L, Martin GS. The role of diet on the gut microbiome, mood and happiness. medRxiv. 2023.
185. Yu Y, Shen Q, Lai Y, et al. Anti-inflammatory effects of curcumin in microglial cells. Front Pharmacol. 2018;9:386.
186. Wang H, Yang F, Zhang S, Xin R, Sun Y. Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation. NPJ Parkinsons Dis. 2021;7:70.
187. De Sciscio M, Bryant RV, Haylock-Jacobs S, et al. Faecal microbiota transplant in Parkinson’s disease: pilot study to establish safety & tolerability. NPJ Parkinsons Dis. 2025;11:203.
188. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66-72.
